Skip to Content
Merck
CN

D-035

Diltiazem hydrochloride solution

1.0 mg/mL in acetonitrile (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C22H27ClN2O4S
CAS Number:
33286-22-5
Molecular Weight:
450.98
NACRES:
NA.24
PubChem Substance ID:
329798601
UNSPSC Code:
41116107
EC Number:
200-835-2
MDL number:
MFCD00069252

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI key

HDRXZJPWHTXQRI-BHDTVMLSSA-N

InChI

1S/C22H26N2O4S.ClH/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3;/h5-12,20-21H,13-14H2,1-4H3;1H/t20-,21+;/m1./s1

SMILES string

Cl.COc1ccc(cc1)[C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in acetonitrile (as free base)

technique(s)

gas chromatography (GC): suitable, liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

2-8°C

Quality Level

300

Gene Information

human ... CACNA1C(775), CACNA1D(776), CACNA1F(778), CACNA1S(779)

Related Categories

General description

A Certified Spiking Solution® produced for use in clinical toxicology, forensic analysis, or pharmaceutical research applications by GC/Ms or LC/MS. Diltiazem is a pharmaceutical drug in the calcium channel blocker class. Diltiazem is prescribed for the treatment of hypertension and heart conditions such as angina pectoris and some types of arrhythmia.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

pictograms

FlameExclamation mark
GHS02,GHS07

signalword

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

Storage Class

3 - Flammable liquids

wgk

WGK 2

flash_point_f

35.6 °F - closed cup

flash_point_c

2 °C - closed cup

Regulatory Information

危险化学品
This item has

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Toshio Obata et al.
Clinical biochemistry, 46(1-2), 164-166 (2012-09-25)
The interaction between the PKC and oxygen free radicals. The present study examined the effects of lysophosphatidylcholine (LPC), an endogenous amphophilic lipid metabolite, on 1-methyl-4-phenylpyridinium ion (MPP(+))-induced hydroxyl radical (()OH) generation in rat striatum. LPC (50 μM) increased ()OH formation
Ronald W Day
Congenital heart disease, 8(1), 71-77 (2012-08-16)
Right heart catheterization is performed in patients with pulmonary arterial hypertension to determine the severity of disease and their pulmonary vascular reactivity. This study sought to determine whether the acute pulmonary vasodilatory effects of diltiazem and oxygen with nitric oxide
Anna Krupa et al.
AAPS PharmSciTech, 13(4), 1120-1129 (2012-09-04)
Directly compressible co-processed excipient systems facilitate orodispersible tablets (ODTs) manufacturing. Despite several excipient systems available, it is reported that the incorporation of high drug dose into the tablet mass may negatively affect both disintegration and mechanical properties. Therefore the influence
[Optimum heart rate - the current goal of cardiovascular therapy. Position statement of the Polish Cardiac Society Working Group on Cardiovascular Drug Therapy].
Jarosław D Kasprzak et al.
Kardiologia polska, 70(10), 1081-1094 (2012-10-20)
Andrew P Ambrosy et al.
The American journal of cardiology, 110(11), 1623-1626 (2012-09-04)
Five patients with primary colorectal adenocarcinoma or anal squamous cell carcinoma were started on a 2-weeks-on, 1-week-off capecitabine dosing regimen in addition to other chemotherapeutic agents and/or radiation. Within the first few doses, patients experienced chest pain and/or dyspnea at
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service